KRAS and neoplasm: Future work will involve synthesising aglycone or pro-drug derivatives to maximise membrane permeability, employing free-energy perturbation and enhanced-sampling molecular dynamics to characterise binding energetics across KRAS mutants, and confirming pathway suppression in KRAS-dependent tumour models.